Navigation Links
Metabolex Names Zhao, Martin to Executive Posts
Date:7/7/2008

HAYWARD, Calif., July 7 /PRNewswire/ -- Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced that it has promoted Zuchun 'Spring' Zhao to Vice President of Chemical Sciences, and Robert Martin to Vice President of Project and Portfolio Management.

"These appointments represent a significant development in our company in support of our expanding research and clinical pipeline," said Charles McWherter, Ph.D., Senior Vice President of Research and Preclinical Development. "Spring brings a winning combination of creativity in medicinal chemistry along with strong credentials in all aspects of drug discovery and development." Dr. McWherter continued, "Rob is an exceptional asset to Metabolex. He comes with the focus on execution of a biotech but with the savvy of his formative years in pharmaceutical research. Rob is a real master of integrating portfolio strategy with practical operational alternatives."

Dr. Zhao joined Metabolex in 2000 as the head of chemistry, and was instrumental in building the chemistry department. Over the past eight years, he has served in a variety of operational and leadership roles, most recently leading drug discovery projects from lead identification to clinical trials. Earlier in his career, Dr. Zhao worked at Berlex where he contributed to the advancement of several compounds. Dr. Zhao holds a Ph.D. from the University of California Los Angeles, is an inventor on several patents and has published numerous scientific papers in the field of drug discovery.

Dr. Martin joined Metabolex in 2004 and has served the company in a variety of preclinical development and project management positions, most recently as Senior Director of Portfolio Management. He has played a key role in a number of projects in the Metabolex pipeline. Prior to joining the company, he spent ten years with Roche where in his last position -- in the research strategy group -- he focused on improving the productivity of the global research organization. Dr. Martin holds a Ph.D. from the University of California Davis.

About Metabolex

Metabolex is a privately-held biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, with an emphasis on type 2 diabetes. Metabolex has drawn on its deep understanding of diabetes to create a large database of genes involved in diabetes and to build a rich pipeline of product candidates and drug discovery targets. The company has four clinical-stage compounds: MBX-102/JNJ 39659100, which has completed three Phase 2 trials; MBX-2044, which has completed a Phase 2a trial; MBX-8025, currently being studied in a Phase 2 trial in patients with dyslipidemia; and MBX-2982, currently being studied in a Phase 1 trial. Ortho-McNeil, Inc. has the exclusive right to develop and commercialize MBX-102/JNJ 39659100. For additional information about Metabolex and its development pipeline, visit http://www.metabolex.com.


'/>"/>
SOURCE Metabolex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Metabolex Appoints Donald Hill as Chief Financial Officer
2. KGI Names Kerry Howell Vice President for Advancement
3. Vical Names Andrew de Guttadauro Vice President, Corporate Development
4. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
5. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
6. CryoLife Names Philip Theodore as Vice President, General Counsel
7. Genstar Names Michael Hurt to Its Strategic Advisory Board
8. PPD Names Daniel Darazsdi as Chief Financial Officer
9. Society of Laproendoscopic Surgeons Names Starion Instruments 2007 Innovator of the Year
10. Cadence Pharmaceuticals Names Malvina Laudicina Vice President of Regulatory Affairs and Quality Assurance
11. Mpex Pharmaceuticals Names Dr. Jeffery Loutit as Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2017)... ... September 21, 2017 , ... Vixiar Medical announced today ... manufacturing functions to The LaunchPort™ Accelerator at the City Garage in Port Covington. ... manufacturing and business services to its Residents. , Vixiar Medical recently closed ...
(Date:9/21/2017)... MA (PRWEB) , ... September 21, 2017 , ... ... proprietary clinical client portal. Each relaunch of the portal includes new features that ... and medical device companies seek to remain at the forefront of medical advancements, ...
(Date:9/21/2017)... GREENVILLE, S.C. (PRWEB) , ... September 21, 2017 ... ... River turned bright neon green this month, the response was swift and efficient ... Group ( RRWQG ). RRWQG is made up of more than 50 stakeholders, ...
(Date:9/20/2017)... ... 2017 , ... The award-winning producers behind the American Farmer ... innovations aimed at helping farmers solve the problem of nitrogen loss. The upcoming ... 8:30aET on RFD-TV. Check your local listings for more info. , As ...
Breaking Biology Technology:
(Date:4/4/2017)... April 4, 2017   EyeLock LLC , a ... the United States Patent and Trademark Office (USPTO) has ... the linking of an iris image with a face ... represents the company,s 45 th issued patent. ... very timely given the multi-modal biometric capabilities that have ...
(Date:3/30/2017)... 2017 Trends, opportunities and forecast in this ... technology (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, ... end use industry (government and law enforcement, commercial and ... and others), and by region ( North America ... Asia Pacific , and the Rest of the ...
(Date:3/24/2017)... The Controller General of Immigration from Maldives Mr. ... have received the prestigious international IAIR Award for the most innovative ... ... Maldives Immigration ... Algeen (small picture on the right) have received the IAIR award for ...
Breaking Biology News(10 mins):